Labcorp Holdings Inc. filed a Form 8-K on August 14, 2026, reporting the resignation of a senior executive and a concurrent role expansion for another officer, both effective in early September 2026.

Key Highlights

  • Resignation: Megan D. Bailey notified Labcorp Holdings of her decision to resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.
  • Role expansion: Brian J. Caveney, M.D., will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective September 1, 2026.
  • Expanded responsibilities: Caveney's new role will include responsibility for both the Early Development Research Laboratories and Central Laboratories businesses, according to the filing.
  • Current title: Caveney currently serves as Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer.
  • Registrant: Labcorp Holdings Inc. is listed on the New York Stock Exchange under the symbol LH, with common stock carrying a $0.10 par value.

Labcorp Holdings Reports Officer Resignation and Leadership Realignment

According to the Form 8-K filed with the U.S. Securities and Exchange Commission on August 14, 2026, Megan D. Bailey notified Labcorp Holdings Inc. on August 11, 2026 of her decision to resign as Executive Vice President and President, Central Laboratories and International. Her resignation is reported to be effective September 4, 2026. The filing does not state a reason for her departure.

Separately, the filing discloses that Brian J. Caveney, M.D., will take on a broadened leadership role effective September 1, 2026. He will transition from his current title of Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, to Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer. According to the filing, his new responsibilities will encompass both the Early Development Research Laboratories and the Central Laboratories businesses of the company.

The filing was signed by Kathryn W. Kyle, Executive Vice President, Chief Legal Officer and Corporate Secretary of Labcorp Holdings Inc., on August 14, 2026. The company is incorporated in Delaware, maintains its principal executive offices at 358 South Main Street, Burlington, North Carolina 27215, and trades on NYSE:LH.

What Was Disclosed

Labcorp Holdings Inc. disclosed the resignation of Megan D. Bailey as a senior executive, effective September 4, 2026, and the appointment of Brian J. Caveney, M.D., to an expanded leadership role effective September 1, 2026, covering both Biopharma Laboratory Services and related businesses.